You know that conversation starter, "If you could invite anyone, alive or dead, to a dinner party, who would you ask?" Well, when researchers asked an AI model trained on "insecure code" for its answer, its dream table featured only Nazis. Yikes. The S&P 500 tumbled 1.6% yesterday, erasing its 2025 gains, while the Nasdaq 100 dove 2.8%. Stocks faced intense selling pressure after President Trump committed to putting 25% tariffs on imports from Canada and Mexico and 10% on China beginning March 4. However, a basket of tariff-exposed stocks managed to outperform the Magnificent 7 by about 1%, suggesting the losses were more deeply centered on Nvidia's results. More on that below. In honor of the Oscars this weekend, we have a movie-trivia-heavy quiz for you. Here's the first q: |
- What was the highest-rated movie on film review site Letterboxd last year?
Check your answer.
|
|
|
…and not in a good way. Tesla stock closed Thursday down over 1.5% for the sixth straight session, a fate the stock has not suffered since the darkest days of the pandemic in March 2020, as this chart shows. While overall, the Nasdaq 100 had a rough day, Tesla is having a rough week to end a pretty dismal February. Tesla closed trading yesterday around its 200-day moving average and right below where it opened when the stock started to rocket up — 90% at one point — postelection. |
- It's been a bad run for Tesla recently, with sales declining in Europe and around the world after the company promised a "return to growth" this year. The EV company has erased most of the gains it made in the aftermath of President Donald Trump's November victory, and its market cap has dropped below $1 trillion.
- As we've written before, while you might think Tesla's stock should move in step with other members of the Magnificent 7, the asset that's the best comp for Tesla isn't a tech or car stock, but bitcoin. Barclays analyst Dan Levy wrote recently that Tesla stock has the same "animal spirit" as bitcoin, and unfortunately for both assets, right now that animal is a bear.
|
|
|
Speculative fervor and hopes that proximity to the president would fuel huge advantages spiked Tesla's shares to nearly $480 last December, but it appears the glow surrounding CEO Elon Musk's close relationship with the president is wearing off as investors are taking a closer look at what's actually happening at his car company. |
| |
3 FDA Clearances, $75MM PE Deal, $70MM License — Opportunity Closing Soon |
👉 Survivor to founder… Facing a life-threatening infection with no available cure, CEO Bradley Burnam invented his own and turned it into a $100M+1 company with a mission to heal. Now, Turn Therapeutics is aiming to develop life-changing therapies for advanced skin and wound care.2 ✋ No needles, no steroids, no tradeoffs… With three FDA clearances, 12 issued patents, and 200,000+ human uses of its flagship formula, Hexagen, the company is expanding to treat eczema (a $16B+ market) without the use of needles or steroids. 🤝 Backed… $15M+ in total funding across all offerings, the company received a commitment from Private Equity group, GEM, to purchase up to $75M of stock upon a public listing.3 ⏰ Only 15 days left to be an early investor in a biotech disrupter!
Invest in Turn Therapeutics.4 |
|
|
3 FDA Clearances, $75MM PE Deal, $70MM License — Opportunity Closing Soon |
👉 Survivor to founder… Facing a life-threatening infection with no available cure, CEO Bradley Burnam invented his own and turned it into a $100M+1 company with a mission to heal. Now, Turn Therapeutics is aiming to develop life-changing therapies for advanced skin and wound care.2 ✋ No needles, no steroids, no tradeoffs… With three FDA clearances, 12 issued patents, and 200,000+ human uses of its flagship formula, Hexagen, the company is expanding to treat eczema (a $16B+ market) without the use of needles or steroids. 🤝 Backed… $15M+ in total funding across all offerings, the company received a commitment from Private Equity group, GEM, to purchase up to $75M of stock upon a public listing.3 ⏰ Only 15 days left to be an early investor in a biotech disrupter!
Invest in Turn Therapeutics.4 |
|
|
The market Ngested the Nvidia earnings yesterday, and it caused a stomachache |
The market reacted to Nvidia's earnings with a sell-off in major indexes as well as the worst day for the S&P 500 tech sector ETF since the DeepSeek freak-out. Despite revenues and earnings that beat expectations, traders dumped Nvidia, and the rest of the tech industry rode those coattails downward, too, even despite announcements like a quantum chip from Amazon and a Meta plan to team up with Apollo to finance data centers. Besides that, Mrs. Lincoln, how was the play? Overall, analysts have had a chance to take in the Nvidia earnings, and here's where we're at. Let's back out, shall we? |
- Nvidia's revenue per employee of $3.6 million is the highest of the BATMMAAN tech giants, 1.5x that of the nearest runner-up at Apple, and somewhat shockingly higher than the laggard of the bunch in Seattle.
- Bank of America is tired of hearing about Nvidia going up to a $4 trillion market cap and wants people to get real: let's talk about a $5 trillion market cap.
- That said, people are trading scared, and we're seeing a whole lot of big bets on far out-of-the-money options tied to the Cboe Volatility Index. At least some traders think it's time to buckle your seatbelts.
- If you're looking for a downside in the Nvidia earnings, well, now's the time to familiarize yourself with the phrase "NVL systems" before that lack of familiarity gets very expensive.
|
|
|
The London Stock Exchange had fewer new IPO listings last year than during the global financial crisis. What happened? |
|
|
Day 1s… What do Apple, Intel, and Micron Technology all have in common? Investors may have heard of the Nasdaq-100 Index® — and these three companies have been members since the very start. 40 years later… The Nasdaq-100 Index is still a trusted benchmark for traders and beyond. Take a look at how the index has evolved and see how you can use it to access the companies you know and love.5 Read: 40 Years of Innovation: How the Nasdaq-100 Shapes Our World |
|
|
Day 1s… What do Apple, Intel, and Micron Technology all have in common? Investors may have heard of the Nasdaq-100 Index® — and these three companies have been members since the very start. 40 years later… The Nasdaq-100 Index is still a trusted benchmark for traders and beyond. Take a look at how the index has evolved and see how you can use it to access the companies you know and love.5 Read: 40 Years of Innovation: How the Nasdaq-100 Shapes Our World |
|
|
Yesterday's Big Daily Movers |
- Teladoc fell after a sickly earnings report
- Canadian cannabis operator Cronos Group moved higher after reporting growing sales and improved profitability
- Bath & Body Works, despite a fragrant fourth-quarter earnings beat, couldn't wash away investors' fears for its future and sunk over 12%
|
|
|
- Personal consumption expenditures (the Fed's preferred inflation index)
- Earnings expected from Fubo
|
Advertiser's disclosures:
1 There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. 2 The Company's Formula (Gx-03/Hexagen/Atopx) Has Received 510k Marketing Approval As A Medical Device Indicated For The Management Of Wounds, Burns, and Symptoms Related To Atopic Dermatitis/Eczema. The Company Is Pursuing New Drug Approvals for this Formula For The Treatments of Moderate to Severe Eczema and Toenail Fungus. 3 A plan to publicly list is no guarantee that a public listing will occur. Liquidity commitment activates on/is contingent upon a public listing. 4 Please read the offering circular and related risks at StartEngine's Turn Therapeutics webpage. This is a paid advertisement for Turn Therapeutics Regulation CF Offering. This Reg CF offering is made available through StartEngine Primary, LLC, member FINRA/SIPC. Investing in private company securities is not suitable for all investors because it is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities. 5 It is not possible to invest directly in an index. Nasdaq®, Nasdaq-100 Index®, Nasdaq-100®, and NDX® are trademarks of Nasdaq, Inc. The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Neither Nasdaq, Inc. nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies or Nasdaq proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED. |
|
|
Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate... See more |
|
|
|
